

Clinical trials of olmesartan 40 mg

TrialResults-center www.trialresultscenter.org

1 hypertension

| Trial | Treatments | Patients | Trials design and methods |
|--|---|---|---------------------------|
| olmesartan 40 mg vs olmesartan 20 mg plus a calcium-channel blocker | | | |
| OSCAR , 2011 [NCT00134160] n=578/586 follow-up: | high-dose olmesartan 40 mg per day versus 20-mg/day olmesartan comined with standard dose of amlodipine or azelnidipine | high-risk elderly Japanese hypertension patients | Parallel groups Japan |

More details and results :

- anti hypertensive agents for hypertension in all type of patient at <http://www.trialresultscenter.org/go-Q13>
- angiotensin-receptor blockers for hypertension in all diseases requiring ACEi (HF, CHD, HT,...) at <http://www.trialresultscenter.org/go-Q125>
- anti hypertensive agents for hypertension in patients with additional risk factor at <http://www.trialresultscenter.org/go-Q686>

References

OSCAR, 2011:

Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160). Hypertens Res 2009;32:575-80 [[19444280](https://pubmed.ncbi.nlm.nih.gov/19444280/)] [10.1038/hr.2009.60](https://doi.org/10.1038/hr.2009.60)

2 miscellaneous

| Trial | Treatments | Patients | Trials design and methods |
|--|------------|----------|---------------------------|
| olmesartan 40 mg vs olmesartan 20 mg plus a calcium-channel blocker | | | |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|--|---|---|---------------------------|
| OSCAR , 2011 [NCT00134160] n=578/586 follow-up: | high-dose olmesartan 40 mg per day versus 20-mg/day olmesartan comined with standard dose of amlodipine or azelnidipine | high-risk elderly Japanese hypertension patients | Parallel groups Japan |

More details and results :

- angiotensin-receptor blockers for miscellaneous in all type of patients at <http://www.trialresultscenter.org/go-Q425>

References

OSCAR, 2011:

Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160). Hypertens Res 2009;32:575-80 [19444280] 10.1038/hr.2009.60